Structure Therapeutics raises ~$300M in private placement for GLP-1 pipeline

Structure Therapeutics Inc.

Sold 21.6M ordinary shares and 2.4M non-voting ordinary shares at $12.49/share (~$37.47/ADS) for ~$300M gross proceeds.
Proceeds to fund oral GLP-1R agonist GSBR-1290, next-gen GLP-1/GIPR combo, oral amylin agonist, and operations through at least 2026.
Closing expected on or about Oct 3, 2023; Jefferies and Leerink act as placement agents with 6% fee.
Registration statement to be filed within 45 days of closing to register resale of shares.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Structure Therapeutics Inc. entered into Purchase Agreement with certain institutional investors valued at aggregate gross proceeds of approximately $300 million (effective 2023-09-29).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: aggregate gross proceeds of approximately $300 million
Effective: 2023-09-29

Exact text from the filing

On September 29, 2023, Structure Therapeutics Inc. (the “Company”) entered into a share purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”).

View on SEC.gov

Browse all material agreements →

Structure Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-105038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.